Prof Alimuddin Zumla

Ms Alimuddin ZumlaTel: 07901 638 375
Fax: 020 7679 9311


Professional background

Professor Zumla is the Director of the Centre for Infectious Diseases and International Health at University College London Medical School. He is also consultant infectious diseases physician at UCLH. His London and overseas research activities span the interface between clinical investigation and biomedical science, with the long-term goals of understanding the pathogenesis of important killer infectious diseases afflicting adults and children, and developing methods for better treatment and control.

Prof. Zumla’s research embraces the principles of evidence-based medicine, contributing knowledge through specific clinical, research and training activities in the UK, Europe and in several African countries. A very successful programme of research and training between UCL, UK institutions, and several African, European and USA institutions has been developed. He serves on many national and international advisory committees and his professional international leadership in infectious diseases reflects the NHS's influence on global health.

Research interests

  • Tuberculosis
  • Tropical diseases
  • Respiratory infections
  • Rapid diagnostics for respiratory infections
  • Endocarditis
  • TB drug clinical trials
  • Biomarkers
  • Transrenal DNA and TB in London


1. Cook GC and Zumla A. (Editors): Manson's Tropical
Diseases, 22nd edition, Elsevier Harcourt Brace Publishing
Group, London, 2008

2.  Zumla A and Schaaf S (Editors):  Tuberculosis – a comprehensive clinical treatise (112 chapters and 128 authors). Elsevier, London and USA. (2008)  This is the most comprehensive clinical treatise on TB available. 

3. Griffiths C,  Sturdy P, Brewin P, Bothamley G, Eldridge A, Martineau A, McDonald M, Ramsay J, Levi S, Zumla A, Tibrewal S, Feder G. Educational outreach to promote screening, diagnosis and prevention of tuberculosis in primary care: a cluster randomised controlled trial. The Lancet (2007): 369:1528-1534. 

4. Nunn A, Mwaba P, Mwinga A, Darbyshire J, Chintu C, Zumla A and the LUCOT team.  Double blind, placebo-controlled clinical trial to evaluate the efficacy of co-trimoxazole given as prophylaxis in reducing mortality and morbidity in HIV-infected adults with tuberculosis. British Medical Journal (2008) Jul 10;337:a257. 

5. Zumla A (TB Essay Focus coordinator), and Mullan Z The Lancet, Vol: 367: March 18th 2006: p 938-955. 

6. Zumla A and Mullan Z Lancet commentary: Turning the tide against Tuberculosis. The Lancet (2006) 367: 877. March 18th issue. 

7. Perkins M, Rosicgno G and Zumla A. Progress towards improved tuberculosis diagnosis in developing countries. The Lancet (2006) 367: 942-943.942-943. 

8.  Chintu C, Bhat GJ , Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L,  Zumla A, Gillespie S, Nunn AJ and Gibb DM, on behalf of the CHAP Trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children. A double blind randomized placebo-controlled trial. The Lancet (2004) 364:1865-71. 

 9.  Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, Darbyshire J & Zumla A. Mycobacterium vaccae (SRL172) Immunotherapy as an adjunct to standard anti-tuberculosis therapy in HIV-infected Zambian and Malawian Adults with Pulmonary Tuberculosis –  randomised placebo-controlled clinical trial. The Lancet (2002) 360:1050-1055. 

10. Chintu C, Mudenda V, Lucas S, Andrew Nunn, Kennedy Lishimpi, Daniel Maswahu, Francis  Kasolo, Mwaba P, Bhat G, Hiroshi Terunuma and  Zumla A. Lung diseases at necropsy in African children dying of respiratory illnesses –a descriptive   necropsy study. The Lancet (2002) 360: 985-990.

11. Mwaba P, Cassol S, Nunn A, Pilon R, Chintu C, James M, Zumla A. Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. The Lancet. (2003);362(9401):2067-8. 

12. Mwaba P, Cassol S, Pilon R, Chintu C, Janes M, Nunn A, Zumla A.Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. The Lancet. (2003): 362(9394):1459-60. 

GMC/GDC number: 3050424